Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs iShares Russell 2000 ETF (IWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs iShares Russell 2000 ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while iShares Russell 2000 ETF trades at $301.52. Which is the better fit depends on your goals.
| BIO | IWM | |
|---|---|---|
Market Cap | $9.39B | — |
Sector | Health | — |
52-Week High | $356.25 | $301.69 |
52-Week Low | $241.71 | $225.45 |
Enterprise Value | $9.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
IWM, the iShares Russell 2000 ETF, trades at $301.53, up 1.11% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF tracks US small-cap stocks, which have shown strong performance in 2026, though financial ratios are not applicable as it is a fund. Recent news highlights institutional inflows and small-cap outperformance versus large caps.
Outlook for IWM is positive due to small-cap strength and institutional support, but risks include higher volatility and competition from alternative ETFs. The bullish trend may continue if economic conditions favor small companies, though overbought RSI levels suggest potential near-term pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →
